stockrow
Saturday 7 November 2026
Export RIGL’s income statement to Excel — free account
Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.
- Revenue
- +16.5%
- EPS
- −54.8%
- Free cash flow
- +43.9%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
39.59
6.12
−13.39%
Follow RIGL
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 109.18% | 126.90% | 174.08% | 185.94% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 6 | 6 | |
| 80.16% | 88.46% | 107.04% | 108.34% | ||
ROIC |
13.69% | 16.48% | 29.03% | 30.28% | |
Return on Tangible Assets |
279.89% | 357.90% | 252.00% | 260.43% | |
Average Days of Receivables |
71.50 | 73.90 | 60.81 | 64.20 | |
Free Cash Flow per Share |
4.81 | 0.48 | 4.31 | 4.21 | |
Free Cash Flow |
89.92 | 8.82 | 79.27 | 75.66 | |
Capital Expenditures |
— | (70.57) | — | — | |
| Other line items | |||||
Cash ROIC |
16.52% | 1.69% | 14.12% | 13.30% | |
Accounts Receivable Turnover |
5.63 | 5.77 | 6.55 | 6.30 | |
Accounts Payable Turnover |
3.91 | 4.22 | 4.70 | 3.73 | |
Inventory Turnover |
2.05 | 1.92 | 2.43 | 2.24 | |
Average Days of Payables |
139.82 | 61.41 | 82.62 | 133.77 | |
Days of Inventory on Hand |
193.14 | 219.97 | 214.60 | 214.04 | |
Tax Rate |
3.08 | 2.76 | 1.99 | 2.01 | |
Research and Development Expense of Revenue |
18.94% | 15.78% | 12.19% | 11.31% | |
Selling, General and Administrative Expense of Revenue |
44.42% | 44.16% | 39.64% | 39.38% | |
Share Based Compensation of Revenue |
6.21% | 5.93% | 4.28% | 4.32% | |
Interest Coverage |
18.17 | 15.00 | 18.05 | 17.14 | |
Operating CF/Net income |
0.29 | 0.25 | 0.22 | 0.21 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (40.70) | 0.00 | 0.00 | |
Revenue per Share |
15.40 | 14.93 | 16.28 | 16.36 | |
Operating CF per Share |
4.81 | 4.28 | 4.31 | 4.21 | |
Capex per Share |
0.00 | (3.81) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.26 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026